Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29205132 | 0.91 | HSD11B1 (0.40) | HSD11B1CYP2C19 | |
| SCHEMBL29205165 | 0.86 | HSD11B1 (0.40) | HSD11B1CTSBCTSSCTSKCTSC | |
| SCHEMBL27166085 | 0.84 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL29205127 | 0.84 | ALOX5 (0.42) | HSD11B1 | |
| SCHEMBL27166174 | 0.84 | CTSB (0.38) | HSD11B1CTSBCTSSCTSKCTSC | |
| SCHEMBL29205162 | 0.83 | HSD11B1 (0.38) | HSD11B1CTSBCTSSCTSKCTSC | |
| SCHEMBL29205157 | 0.83 | ALOX5 (0.44) | HSD11B1 | |
| SCHEMBL27166171 | 0.82 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL27166076 | 0.82 | HSD11B1 (0.43) | HSD11B1CTSBCTSSCTSKCTSC | |
| SCHEMBL27204478 | 0.81 | KCNK3 (0.42) | HSD11B1CTSBCTSSCTSKCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022234193-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | FORENDO PHARMA LTD (FI) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | HSD11B1 17/4885CTSB 1925/4885CTSS 1409/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | HSD11B1 11/4885CTSB 2702/4885CTSS 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.